Filing Analysis
Microbot Medical Inc. filed an 8-K to announce the dissemination of a press release containing highlights from its quarterly report for the fiscal quarter ended June 30, 2026.
📋 Key Facts
- The company has filed its Quarterly Report on Form 10-Q for the period ending June 30, 2026.
- A press release was issued on August 11, 2026, providing highlights of the second quarter results.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
Microbot Medical Inc. entered into an addendum to the employment agreement of its CFO, Rachel Vaknin, effective August 1, 2026. The amendment primarily increases her annual base salary to NIS 864,000 (approximately $288,000).
🚩 Red Flags
- Compensation increase for a key officer in a micro-cap environment can sometimes signal cash flow pressure or retention efforts during volatility, though not inherently negative without further context.
📋 Key Facts
- Effective date of salary increase: August 1, 2026.
- New annual base salary for CFO Rachel Vaknin: NIS 864,000.
- Exchange rate used for conversion: 3:1 (NIS to USD), totaling approximately $288,000.
- The agreement is documented as Addendum #4 to her existing Employment Agreement.
Microbot Medical Inc. announced that CEO Harel Gadot will participate in the Society of Robotic Surgery (SRS) annual meeting to discuss endovascular robotic market trends and emerging technologies.
📋 Key Facts
- CEO Harel Gadot to present at the Society of Robotic Surgery (SRS) annual meeting from July 23-26, 2026.
- Presentation topic: Overview of the endovascular robotic market and emerging technologies in peripheral vascular, neurovascular, and cardiovascular spaces.
- The event will be livestreamed on July 24, 2026 (implied by meeting dates) at 10:25 am ET.
Microbot Medical Inc. reported significant operational growth for the second quarter of 2026, noting a greater than 100% increase in both revenue and new customer acquisition compared to Q1 2026.
📋 Key Facts
- Reported >100% revenue growth in Q2 2026 vs Q1 2026 (ended June 30, 2026).
- Reported >100% growth in new customers in Q2 2026 vs Q1 2026.
- Filing date: July 7, 2026.
Microbot Medical Inc. has entered into a Letter of Agreement with Sanmina Corporation to manufacture its LIBERTY® Endovascular Robotic System. The partnership is intended to scale manufacturing capacity and support the company's cost reduction strategy.
📋 Key Facts
- Entered into a Letter of Agreement with Sanmina Corporation on June 30, 2026.
- The agreement focuses on manufacturing the LIBERTY® Endovascular Robotic System.
- Objective is to expand manufacturing capacity for existing and new accounts.
- Agreement aims to support the company's cost reduction strategy.
Microbot Medical Inc. issued an 8-K to announce that the company has received the Innovative Start-Up Award from Surgical Robotics Technology.
📋 Key Facts
- Company won the 'Innovative Start-Up Award' from Surgical Robotics Technology.
- The announcement was made via press release on June 25, 2026.
- The filing is being furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Microbot Medical Inc. announced the adoption of its LIBERTY® Endovascular Robotic System by a globally recognized academic center in Pennsylvania. This marks the company's first account in that state, expanding its footprint to seven states.
📋 Key Facts
- A globally recognized academic center in Pennsylvania has adopted the LIBERTY® Endovascular Robotic System.
- This is the first adoption of the system within the state of Pennsylvania.
- The company now maintains accounts in seven states across the Eastern United States.
Microbot Medical Inc. announced a vendor agreement with Lovell Government Services to facilitate the sale of its LIBERTY Endovascular Robotic System. This agreement provides the company access to over 2,000 U.S. government facilities.
📋 Key Facts
- Agreement entered into on June 16, 2026.
- Partner: Lovell Government Services.
- Target Market: Over 2,000 U.S. government facilities.
- Product: LIBERTY Endovascular Robotic System.
Microbot Medical Inc. announced the acquisition of its first Midwest-based account, specifically a healthcare system located in Michigan.
📋 Key Facts
- The announcement was made on June 9, 2026.
- The new account is a healthcare system in Michigan.
- This represents the company's first entry into the Midwest market.
Microbot Medical Inc. announced the acquisition of its first customer based in North Carolina for the LIBERTY Endovascular Robotic System. This represents a geographic expansion of the company's market penetration into the southeastern United States.
📋 Key Facts
- Date of announcement: June 2, 2026
- Product involved: LIBERTY Endovascular Robotic System
- Market expansion: First customer secured in North Carolina
- Existing presence: Southeast, mid-Atlantic, and northeast U.S.
Microbot Medical Inc. announced it has received regulatory approval from the Israeli Ministry of Health's AMAR Division to market and commercialize its LIBERTY® Endovascular Robotic System in Israel. This approval also enables the company to obtain a Free Sale Certificate to support regulatory submissions in other jurisdictions.
📋 Key Facts
- Received regulatory approval from the Israeli Ministry of Health's AMAR Division on May 26, 2026.
- The approval allows marketing and commercialization of the LIBERTY® Endovascular Robotic System in Israel.
- The approval enables the company to obtain a Free Sale Certificate to support commercial activities in additional jurisdictions.
Microbot Medical Inc. announced it will host an analysts and investors conference call and live webcast on May 18, 2026, at 3:00pm ET. The event is intended to provide updates to the investment community and was disclosed under Regulation FD.
📋 Key Facts
- Conference call and live webcast scheduled for Monday, May 18, 2026, at 3:00pm ET.
- The company provided registration details via a dedicated URL and its investor relations website.
- The press release associated with the announcement was furnished as Exhibit 99.1.
Microbot Medical announced it has successfully transitioned from a limited market release to a full market release of its LIBERTY Endovascular Robotic System. The company reported that Q2 2026 revenue has already exceeded Q1 2026 revenue, indicating accelerating adoption of the technology.
📋 Key Facts
- Revenue was first recorded in Q1 2026 during a limited market release phase.
- The company transitioned to a full market release of the LIBERTY Endovascular Robotic System in Q2 2026.
- As of May 14, 2026, Q2 revenue has already surpassed the total revenue recorded in Q1.
- The LIBERTY System is seeing increased utilization across multiple sales territories.
Microbot Medical announced the full market release of its LIBERTY Endovascular Robotic System and reported securing new accounts following the Society of Interventional Radiology annual meeting. The company highlighted that two of these new accounts were previous participants in its ACCESS-PVI pivotal clinical trial.
📋 Key Facts
- Commencement of the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System.
- Reported strong interest from physicians and hospital executives at the Society of Interventional Radiology (SIR) annual meeting.
- Successfully won accounts in key sales territories.
- Two new accounts were former participants in the Company’s ACCESS-PVI pivotal clinical trial.
- The filing is a Regulation FD disclosure under Item 7.01.
Microbot Medical Inc. announced the appointment of Alon Tamir as Vice President of Sales for the EMEA region to lead international expansion. The company is focusing on the commercial rollout of its LIBERTY Endovascular Robotic System in Europe, the Middle East, and Asia.
📋 Key Facts
- Appointment of Alon Tamir as VP of Sales, EMEA, effective April 30, 2026.
- The role focuses on developing go-to-market strategies and distribution partnerships in Europe, the Middle East, and Asia.
- The company continues to prioritize its U.S. commercial efforts while building international regulatory and operational capabilities.
- The expansion leverages the commercial launch of the LIBERTY Endovascular Robotic System.
Microbot Medical Inc. announced that new joint safety guidelines from major interventional radiology societies (SIR and CIRSE) regarding occupational protection may enhance the commercial adoption of its LIBERTY Endovascular Robotic System.
📋 Key Facts
- The Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) released updated joint guidelines on April 22, 2026.
- The guidelines provide safety guidance for physicians, radiographers, and nurses involved in interventional radiology procedures.
- The Company believes these guidelines strengthen the commercial position of its LIBERTY Endovascular Robotic System, which likely offers radiation protection benefits.
- The information was furnished under Item 7.01 and is not deemed 'filed' for regulatory purposes.
Microbot Medical Inc. announced that its CEO, Harel Gadot, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The presentation will focus on the recent Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System and the company's commercial growth strategy.
📋 Key Facts
- CEO Harel Gadot is scheduled to present live at 10:15 a.m. ET on Wednesday, April 15, 2026.
- The presentation will highlight the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System.
- Management intends to discuss strategic positioning regarding physician radiation risks, physical strain, and healthcare staffing issues.
- The filing includes a press release furnished as Exhibit 99.1.
Microbot Medical announced the full U.S. market release of its LIBERTY Endovascular Robotic System following a successful limited release phase. The company is aggressively expanding its commercial footprint, doubling its sales territories from four to eight with a target of twelve by the end of 2026.
📋 Key Facts
- Full U.S. market release of LIBERTY® Endovascular Robotic System announced on April 13, 2026.
- The system has been adopted by major healthcare providers including Emory Healthcare and Tampa General Hospital.
- Successful commercial use reported in procedures such as Prostate Artery Embolization (PAE) and Y90 deliveries.
- Sales force expansion from 4 to 8 territories currently, with a goal of 12 territories by year-end 2026.
Microbot Medical Inc. has filed a prospectus supplement to its existing shelf registration statement to launch an 'at the market' (ATM) offering program for up to $39,230,691 of its common stock. The offering will be conducted through H.C. Wainwright & Co., LLC as the sales agent.
🚩 Red Flags
- Potential for significant shareholder dilution, especially common in micro-cap companies using ATM facilities.
- Continuous reliance on equity financing to fund operations.
📋 Key Facts
- The company may sell up to $39,230,691 in common stock through an ATM program.
- H.C. Wainwright & Co., LLC is acting as the sales agent.
- The offering is based on an At the Market Offering Agreement dated June 10, 2021, as amended on July 1, 2024.
- Sales will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-275634).
- Transactions will be made at market prices prevailing at the time of sale on the Nasdaq Capital Market.
Microbot Medical announced the successful completion of robotic peripheral endovascular procedures at Emory Healthcare using its LIBERTY® Endovascular Robotic System. The procedures successfully targeted benign prostatic hyperplasia (BPH) and liver cancer, marking a clinical milestone for the company's technology.
📋 Key Facts
- Joint press release issued with Emory Healthcare on March 26, 2026.
- Emory interventional radiologists successfully used the LIBERTY® Endovascular Robotic System for minimally invasive treatments.
- Clinical applications demonstrated include benign prostatic hyperplasia (BPH) and liver cancer.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure).
Microbot Medical Inc. announced the publication of a peer-reviewed article in the Journal of Vascular and Interventional Radiology (JVIR) regarding its disposable endovascular robotic system. The study focused on the feasibility of the system for arterial peripheral vascular interventions.
📋 Key Facts
- The article is titled 'In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study.'
- The lead author, Dr. Francois Cornelis, is the Lead Principal Investigator for the LIBERTY ACCESS PVI Pivotal Study.
- The filing was made under Item 7.01 (Regulation FD Disclosure) on March 24, 2026.
- The publication provides clinical validation for the company's robotic technology in a multicenter setting.
Microbot Medical Inc. announced its participation in the Roth Annual Growth Conference scheduled for March 22-24, 2026. The company's CEO, Harel Gadot, will present a fireside Q&A and the company has released updated investor presentation materials.
📋 Key Facts
- Participation in the Roth Annual Growth Conference in Laguna Niguel, CA, from March 22-24, 2026.
- CEO Harel Gadot will present a live fireside Q&A on March 23, 2026, at 4:00 pm PT.
- Updated investor presentation materials were released as Exhibit 99.2.
- The information is furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Microbot Medical Inc. announced its scheduled participation in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference. CEO Harel Gadot is set to deliver a live presentation on March 19, 2026.
📋 Key Facts
- The company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference held March 16-19, 2026.
- CEO, President, and Chairman Harel Gadot will present live on March 19, 2026, at 8:40 am ET.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
- A press release regarding the event was furnished as Exhibit 99.1.
Microbot Medical issued a press release on March 4, 2026, commending the American Medical Association's (AMA) efforts to protect healthcare professionals from ionizing radiation. The filing is a standard Regulation FD disclosure and does not report material financial or operational changes.
📋 Key Facts
- The report was filed on March 4, 2026, under Item 7.01.
- The company expressed support for AMA initiatives regarding ionizing radiation protection for healthcare workers.
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Exhibit 99.1 contains the full text of the press release.
Microbot Medical Inc. issued a press release on March 3, 2026, confirming its operational and commercial stability despite ongoing geopolitical events in the Middle East. The disclosure was made under Item 7.01 to provide a status update to investors regarding business continuity.
🚩 Red Flags
- Implicit exposure to geopolitical risk in the Middle East, which necessitated a public reassurance of stability.
📋 Key Facts
- The report was filed on March 3, 2026, under Item 7.01 (Regulation FD Disclosure).
- The company confirmed 'continued operational and commercial stability' in the face of Middle East geopolitical events.
- The information was furnished via Exhibit 99.1 and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act.
- The filing was signed by Harel Gadot, CEO, President, and Chairman.
Microbot Medical Inc. entered into amended employment agreements with its CTO, CFO, and CMO, providing for salary increases and higher bonus potentials. The company also authorized a one-time special bonus of $140,000 for CEO Harel Gadot.
📋 Key Facts
- CTO Simon Sharon's annual base salary increased to NIS 1,008,000 (approx. $276,000 USD) with a maximum bonus of 50% of base salary.
- CFO Rachel Vaknin's annual base salary increased to NIS 756,000 (approx. $207,000 USD) with a maximum bonus of 50% of base salary.
- CMO Juan Diaz-Cartelle's maximum annual bonus was increased to 50% of base salary.
- CEO Harel Gadot was awarded a special bonus of approximately $140,000, effective February 18, 2026.
- Salary reviews for the CTO and CFO will now be conducted annually by the Compensation Committee based on performance metrics without requiring further formal amendments.
Microbot Medical Inc. announced that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System. This commercial milestone follows the company's recent FDA 510(k) clearance for the device.
📋 Key Facts
- Tampa General Hospital is the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System.
- The adoption follows the company's recent FDA 510(k) clearance for the system.
- The announcement was made via a press release on February 24, 2026.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure).
Microbot Medical Inc. filed a routine Regulation FD disclosure announcing that CEO Harel Gadot will participate as a panelist at The Surgical Disruptive Technology Summit, part of the SAGES NBT Innovation Weekend, held February 19-21, 2026 in Houston, TX. No material business developments were disclosed.
🚩 Red Flags
- CEO serves as both President and Chairman, concentrating governance authority — though common for micro-caps, it reduces board independence
📋 Key Facts
- CEO Harel Gadot is a featured panelist at The Surgical Disruptive Technology Summit (SAGES NBT Innovation Weekend)
- Conference held February 19-21, 2026 in Houston, TX
- Information is 'furnished' under Item 7.01, not 'filed' — standard Reg FD treatment with no Section 18 liability
- Company is listed on NASDAQ Capital Market under ticker MBOT
- Harel Gadot holds triple role: CEO, President, and Chairman of the Board
Microbot Medical Inc. issued an 8-K to announce that its LIBERTY® Endovascular Robotic System was featured at the International Symposium on Endovascular Therapy (ISET) conference held in Miami Beach, Florida.
📋 Key Facts
- The company's LIBERTY® Endovascular Robotic System was showcased at the ISET conference from February 9-12, 2026.
- The announcement is a Regulation FD disclosure (Item 7.01) and is considered 'furnished' rather than 'filed'.
- The filing includes a press release as Exhibit 99.1.
Microbot Medical Inc. issued an 8-K to announce its participation in the Society of Interventional Oncology (SIO) annual meeting held from February 4-8, 2026. The company intends to use this event to showcase physician feedback and practical insights regarding its LIBERTY Endovascular Robotic System.
📋 Key Facts
- Company is attending the SIO annual meeting in Savannah, GA (Feb 4-8, 2026).
- The event coincides with the limited market release of the LIBERTY Endovascular Robotic System.
- Focus of participation is sharing physician experiences and practical insights from hospital use.
Microbot Medical Inc. issued an 8-K to reaffirm its 2025 achievements and outline anticipated key milestones for the year 2026.
📋 Key Facts
- Filed on January 12, 2026.
- The filing is a press release regarding company achievements and future outlook (Exhibit 99.1).
- Reaffirms successful completion of 2025 objectives.
Microbot Medical Inc. announced that Emory University Hospital has become the first hospital globally to adopt its LIBERTY Endovascular Robotic System. The company is also collaborating with the hospital to establish an Endovascular Robotics Program in interventional radiology.
📋 Key Facts
- Emory University Hospital (Atlanta-based) is the first hospital to adopt the LIBERTY Endovascular Robotic System for patient care.
- The Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology.
- The announcement was made via press release on November 26, 2025.
Microbot Medical Inc. announced the limited commercial availability of its LIBERTY® Endovascular Robotic System in the United States. The rollout will target high-volume procedure regions where preliminary demand has already been identified.
📋 Key Facts
- LIBERTY® Endovascular Robotic System is now commercially available in the U.S. on a limited basis.
- The commercial release targets selected high procedure volume regions.
- Preliminary demand for the system was noted prior to this launch.
Microbot Medical Inc. announced its first commercial exhibition of the LIBERTY Endovascular Robotic System at an upcoming oncology symposium and confirmed the completion of hiring for its commercial leadership team.
📋 Key Facts
- Company will exhibit the LIBERTY Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami, FL (Oct 17-19, 2025).
- This marks the first medical meeting where the company is commercially exhibiting following FDA 510(k) clearance.
- The company has completed hiring and onboarding of its commercial leadership team.
Microbot Medical Inc. has entered into a partnership with a U.S.-based third-party logistics (3PL) company to facilitate the commercialization of its FDA-cleared LIBERTY Endovascular Robotic System.
📋 Key Facts
- Partnered with a U.S.-based 3PL company for product commercialization.
- The partnership supports the LIBERTY Endovascular Robotic System, which is already FDA-cleared.
- Limited market release of the LIBERTY System is expected in Q4 2025.
- Broader market launch is anticipated in April 2026 during the Society of Interventional Radiology conference.
Microbot Medical Inc. announced the exercise of existing preferred investment options (PIOs) resulting in the issuance of 1,324,488 shares of common stock at $2.10 per share. The transaction also involved the issuance of new Series J PIOs and additional options to H.C. Wainwright & Co., LLC.
🚩 Red Flags
- Continued issuance of equity/options to existing holders and advisors suggests ongoing need for capital or compensation via dilution.
📋 Key Facts
- Holder exercised 1,324,488 series H preferred investment options (Existing PIOs).
- Exercise price was $2.10 per share.
- The transaction resulted in the issuance of 1,324,488 new series J preferred investment options (New PIOs) to the Holder.
- 66,224 Wainwright PIOs were issued to H.C. Wainwright & Co., LLC.
- This is the third and final exercise under a Letter Agreement dated September 14, 2025.
- The shares underlying the exercised options are registered on Form S-3 (effective April 2, 2025).
Microbot Medical Inc. announced the exercise of 600,000 preferred investment options (PIOs) for common stock at $2.10 per share, resulting in the issuance of new Series J PIOs to the holder and additional PIOs to H.C. Wainwright & Co., LLC. The company also noted a prior exercise of shares on September 23, 2025, which generated approximately $896,000 in gross proceeds.
🚩 Red Flags
- Continuous issuance of preferred investment options (PIOs) suggests a reliance on private placements/inducement agreements to raise capital.
- The rapid succession of option exercises (Sept 14, Sept 23, Sept 29) indicates high cash burn and immediate need for liquidity.
📋 Key Facts
- Holder exercised 600,000 series H PIOs for common stock at an exercise price of $2.10 per share on September 29, 2025.
- The holder received 600,000 new series J preferred investment options (New PIOs) as part of the transaction.
- 30,000 Wainwright PIOs were issued to H.C. Wainwright & Co., LLC.
- 1,324,488 remaining series H PIOs are expected to be exercised on or before October 15, 2025.
- On September 23, 2025, the company raised approximately $896,000 through the exercise of 374,167 shares at prices between $1.875 and $2.6625.
Microbot Medical Inc. announced that the Japanese Patent Office has granted its first patent in Japan for its core LIBERTY® System technology, which involves a compact robotic device for surgical tool manipulation.
📋 Key Facts
- The Japanese Patent Office granted a patent covering the core LIBERTY® System technology.
- The technology relates to a compact robotic device designed for driving and manipulating movement of at least one elongate surgical tool.
- This marks the Company's first patent granted in Japan.
Microbot Medical Inc. announced that CEO Harel Gadot will participate in a media interview on Benzinga All Access to discuss the recent FDA clearance of the LIBERTY® system and U.S. commercialization plans.
📋 Key Facts
- CEO Harel Gadot scheduled for an interview on Benzinga All Access on September 24, 2025, at 10:45am ET.
- The discussion will focus on the recent FDA clearance of the LIBERTY® product.
- The company intends to discuss commercialization strategies in the U.S. peripheral endovascular space.
Microbot Medical Inc. announced the granting of special one-time cash bonuses to its CEO, CTO, and other executive officers, as well as one-time payments to non-management Board members.
🚩 Red Flags
- Related-party transactions: Significant cash outflows to insiders/executives.
- Timing/Context: Bonuses granted despite potential micro-cap liquidity constraints common in medical device startups.
- Potential governance concern regarding the justification of 'repayment' for previous salary waivers.
📋 Key Facts
- CEO Harel Gadot received a $158,115 bonus.
- CTO Simon Sharon received approximately $64,200.
- Executive Rachel Vaknin received approximately $32,500.
- Non-management Board members authorized to receive one-time payments between $30,000 and $45,000 each.
- The Compensation Committee cited that executives had previously waived 30-50% of their prorated annual base salary in part of 2023 as a reason for the bonuses.
Microbot Medical Inc. entered into an inducement agreement to facilitate the exercise of existing preferred investment options (PIOs) by issuing new PIOs at a significantly higher strike price ($4.50). The transaction is designed to raise approximately $29.2 million in gross proceeds through two closings.
🚩 Red Flags
- Significant dilution: The transaction involves the issuance of up to 13,989,115 new PIO shares at $4.50.
- Related-party transaction: An associated person of Wainwright participated in the transaction, exercising existing PIOs for ~$4.9 million.
- High cost of capital: The company is paying substantial fees (7% cash + 1% management fee) and issuing additional warrants/PIOs to the placement agent.
- Liquidity restriction: The company agreed to a 90-day restriction on the issuance or sale of common stock following the First Closing.
📋 Key Facts
- Company entered into an inducement agreement on September 14, 2025.
- First Closing (Sept 16, 2025) raised ~$25.2 million from existing PIO holders.
- Second Closing expected by Oct 15, 2025, to raise ~$4.0 million.
- New PIOs issued at an exercise price of $4.50 per share (up from previous prices of $1.50-$2.13).
- The company will issue new series J preferred investment options to holders who exercised existing series F, G, H, and I options.
- H.C. Wainwright & Co., LLC is acting as the placement agent with a 7% cash fee and a 1% management fee.
Microbot Medical Inc. released updated investor presentation materials in connection with the H.C. Wainwright Annual Investor Conference. The filing includes a live webcast announcement featuring CEO Harel Gadot.
📋 Key Facts
- Company attended the H.C. Wainwright Annual Investor Conference from September 8-10, 2025.
- CEO Harel Gadot presented live on Tuesday, September 9, 2025.
- Updated presentation materials were released via the company's website and furnished as Exhibit 99.1.
Microbot Medical Inc. announced that the FDA has granted 510(k) clearance for its LIBERTY® Endovascular Robotic System, a single-use, remotely operated robotic system. This regulatory milestone enables the company to begin commercialization in the U.S. market.
📋 Key Facts
- FDA granted 510(k) clearance for the LIBERTY® Endovascular Robotic System on September 8, 2025.
- The system is described as the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
- Company aims to target approximately 2.5 million annual U.S. peripheral vascular procedures.
- CEO Harel Gadot will present at the H.C. Wainwright Annual Investor Conference on September 9, 2025.
Microbot Medical Inc. announced the exercise of preferred investment options resulting in the issuance of over 4 million new common shares. The transaction generated approximately $8.6 million in gross proceeds for the company.
🚩 Red Flags
- Significant dilution to existing shareholders due to the issuance of over 4 million new shares.
- The shares are being issued via preferred investment options, often associated with institutional or insider financing rather than public markets.
📋 Key Facts
- Issued 4,055,870 total shares of Common Stock between August 26 and August 27, 2025.
- Shares issued via exercise of Series H Options (300,000 shares at $2.10/share) and Series I Options (3,755,870 shares at $2.13/share).
- Aggregate gross proceeds generated: approximately $8.6 million.
- Total common stock outstanding as of August 27, 2025: approximately 52,569,762 shares.
Microbot Medical Inc. announced the exercise of various preferred investment options (Series E, G, and H) resulting in the issuance of 2,967,953 common shares. The transaction generated approximately $5.9 million in gross proceeds between August 11 and August 25, 2025.
🚩 Red Flags
- Significant dilution: The issuance of nearly 3 million shares increases the total share count significantly.
- Potential for secondary market selling: Shares underlying Series E, G, and H options are registered on Form S-3 for resale by holders.
📋 Key Facts
- Total shares issued: 2,967,953 common stock shares.
- Aggregate gross proceeds: Approximately $5.9 million (before fees/expenses).
- Series E exercise price: $1.50 per share (104,103 options).
- Series G exercise price: $1.75 per share (467,144 options).
- Series H exercise price: $2.10 per share (2,349,488 options).
- Additional 47,218 shares issued to a former director via incentive options.
- Total common stock outstanding as of August 25, 2025: ~48,513,892 shares.
Microbot Medical Inc. announced that the USPTO has granted a patent for its modular robotic surgical system. This patent is intended to expand the company's intellectual property portfolio and potentially increase the total addressable market (TAM) for its LIBERTY device.
📋 Key Facts
- USPTO granted a patent covering a modular robotic surgical system with independently attachable tool-receiver units.
- The patent aims to enable future adaptation of the LIBERTY device for endovascular procedures.
- The company's IP portfolio now includes 12 patents granted globally and 57 patent applications pending.
Microbot Medical Inc. announced the exercise of Series G preferred investment options resulting in the issuance of over 4.3 million shares and approximately $7.6 million in gross proceeds. Additionally, the company secured a non-dilutive grant from the Israel Innovation Authority (IIA) totaling NIS 2.15 million.
🚩 Red Flags
- Issuance of 4.3M shares represents significant equity movement which may impact existing shareholders.
📋 Key Facts
- Issued 4,344,286 shares of common stock via exercise of Series G preferred investment options.
- Exercise price was $1.75 per share.
- Generated approximately $7.6 million in gross proceeds (before fees and expenses).
- Received a non-dilutive grant from the Israel Innovation Authority (IIA) for NIS 2.15 Million.
- Shares issued are subject to an existing Form S-3 registration statement (No.: 333-284688).
Microbot Medical Inc. announced the exercise of Series G preferred investment options resulting in the issuance of 2,395,715 common shares. The transaction generated approximately $4.2 million in gross proceeds at an exercise price of $1.75 per share.
🚩 Red Flags
- Equity dilution: The issuance of over 2.3 million new shares will dilute existing shareholders.
📋 Key Facts
- Issued 2,395,715 shares of common stock between July 17, 2025, and the filing date.
- Exercise price: $1.75 per share.
- Gross proceeds: Approximately $4.2 million (before fees/expenses).
- Shares were issued via exercise of Series G preferred investment options.
- The shares are subject to a previously filed Form S-3 Registration Statement (No. 333-284688).
Microbot Medical Inc. announced the appointment of Christina Bailey as the new Vice President of Sales on July 22, 2025.
📋 Key Facts
- Appointment of Christina Bailey as Vice President of Sales.
- Announcement date: July 22, 2025.
- The announcement was made via a press release furnished as Exhibit 99.1.
Microbot Medical Inc. announced the issuance of 1,808,336 common shares following the exercise of Series G and Series F preferred investment options. The transaction generated approximately $2.975 million in gross proceeds.
🚩 Red Flags
- Dilution: Issuance of over 1.8 million new common shares increases share count.
- Potential selling pressure: The shares were issued under S-3 registration statements, meaning holders can immediately sell these shares on the open market.
📋 Key Facts
- Issued 1,808,336 total common stock shares between June 18, 2025, and the report date.
- Series G Options: 1,025,000 shares exercised at $1.75/share, totaling ~$1.8 million in gross proceeds.
- Series F Options: 783,336 shares exercised at $1.50/share, totaling ~$1.175 million in gross proceeds.
- Shares were issued under Section 4(a)(2) exemption (non-public offering).
- The shares are subject to existing S-3 registration statements for resale by the option holders.
Microbot Medical Inc. issued an 8-K to announce its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting scheduled for July 16-20, 2025.
📋 Key Facts
- Participation in the Society of Robotic Surgery (SRS) annual meeting in Strasbourg, France.
- Focus on the inaugural Endovascular Robotics session.
- Event dates: July 16-20, 2025.
Microbot Medical Inc. announced its inclusion in the Russell Microcap® Index, effective June 30, 2025. This is a non-material regulatory disclosure under Item 7.01 regarding index membership.
📋 Key Facts
- Company added to the Russell Microcap® Index.
- Effective date of inclusion: June 30, 2025, at market open.
- Filing made pursuant to Item 7.01 (Regulation FD Disclosure).
Microbot Medical Inc. announced the exercise of Series E and Series F preferred investment options, resulting in the issuance of 1,480,504 common shares for approximately $2.22 million in gross proceeds. Additionally, the company reported a new patent grant in China related to its robotic surgical tool handle.
🚩 Red Flags
- Dilutive event: Issuance of over 1.4 million shares via option exercise increases share count.
📋 Key Facts
- Issued 1,480,504 shares of common stock via exercise of Series E and F options.
- Series E Options: 221,062 shares; Series F Options: 1,259,442 shares.
- Exercise price per share was $1.50.
- Gross proceeds generated were approximately $2.22 million (before fees and expenses).
- The issuance occurred between May 13, 2025, and June 17, 2025.
- New patent granted in China by the CNIPA for robotic manipulation of a surgical tool handle.
Microbot Medical Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where shareholders approved significant increases to authorized share counts and the immediate exercisability of certain preferred investment options.
🚩 Red Flags
- Massive expansion of authorized share capital (nearly doubling the total pool), which typically signals significant future dilution.
- Approval of large tranches of preferred investment options that are now immediately exercisable, creating potential immediate selling pressure or conversion into common equity.
📋 Key Facts
- Increased total authorized shares from 61,000,000 to 121,000,000 (including 120,000,000 common and 1,000,000 preferred).
- Shareholders approved the issuance of Series I preferred investment options for up to 12,206,578 shares at $2.13/share.
- Shareholders approved placement agent preferred investment options for 305,164 shares at $2.6625/share.
- Approved the amendment of the 2020 Omnibus Performance Award Plan to increase reserved shares by 2,591,019.
- Ratified Brightman Almagor Zohar & Co. (Deloitte affiliate) as independent auditor for FY2025.
Microbot Medical Inc. announced the hiring of Michael Lytle as Head of Sales Operations & Analytics and provided an updated regulatory timeline for its LIBERTY Endovascular Robotic System.
📋 Key Facts
- Michael Lytle joined as head of Sales Operations & Analytics to expand the commercial team.
- The U.S. launch of the LIBERTY System is projected for Q3 2025.
- FDA 510(k) decision for the LIBERTY Endovascular Robotic System is expected in Q3 2025.
- The updated FDA timeline remains within the original scheduled review window.
Microbot Medical Inc. announced its selection for inclusion in the preliminary list of additions to the Russell Microcap® Index. The index reconstitution is expected to take effect after market close on June 27, 2025.
📋 Key Facts
- Selected for inclusion in the preliminary list of additions to the Russell Microcap® Index by FTSE Russell.
- Announcement date: May 23, 2025 (as per press release reference).
- Reconstitution effective date: After U.S. market close on Friday, June 27, 2025.
- Full index reconstitution expected to be part of the 2025 Russell indexes when markets open on Monday, June 30, 2025.
Microbot Medical Inc. has released updated presentation materials via its website and as an exhibit to this Form 8-K. The filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute a formal update to previous material information.
📋 Key Facts
- The Company released updated presentation materials on April 30, 2025.
- Materials are being posted to the company website: www.microbotmedical.com.
- The filing is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Microbot Medical Inc. announced the exercise of preferred investment options resulting in the issuance of over 1.5 million common shares. The transaction generated approximately $2.3 million in gross proceeds.
🚩 Red Flags
- Dilution: Issuance of 1.5M+ shares will dilute existing common shareholders.
📋 Key Facts
- Issued 1,533,336 shares of common stock on April 21, 2025.
- Shares issued via exercise of 783,336 Series F preferred investment options and 750,000 Series E preferred investment options.
- Exercise price was $1.50 per share.
- Gross proceeds totaled approximately $2.3 million before fees and expenses.
- The issuance was conducted under Section 4(a)(2) exemption (private transaction).
Microbot Medical Inc. announced that it failed to achieve a quorum at its planned special meeting of stockholders on April 11, 2025. Consequently, the company is deferring two specific proposals to its upcoming 2025 Annual Meeting scheduled for June 10, 2025.
🚩 Red Flags
- Failure to achieve a quorum at a special meeting suggests low shareholder engagement or lack of interest in current corporate actions/proposals.
📋 Key Facts
- The Company failed to obtain a quorum at the Planned Special Meeting on April 11, 2025.
- Two proposals originally intended for the special meeting will now be voted on at the 2025 Annual Meeting.
- The 2025 Annual Meeting of stockholders is scheduled for June 10, 2025.
- A Preliminary Proxy Statement was filed with the SEC on April 17, 2025.
Microbot Medical Inc. has amended its bylaws to significantly reduce the quorum requirement for stockholder meetings and announced the upcoming 2025 Annual Meeting of stockholders.
🚩 Red Flags
- Reduction of quorum requirement from a majority to one-third can make it easier for small groups of shareholders to pass resolutions or control meeting outcomes.
- The change in the timing of the Annual Meeting (more than 30 days from previous year) triggered mandatory disclosure requirements regarding proposal deadlines.
📋 Key Facts
- Board approved an amendment to Section 2.5 of the Bylaws on April 14, 2025.
- Quorum requirement for stockholder meetings reduced from a majority of votes cast to one-third (33.3%) of votes entitled to be cast.
- The 2025 Annual Meeting is tentatively scheduled for approximately June 10, 2025.
- Record date for the 2025 Annual Meeting is April 15, 2025.
- Deadline for stockholder proposals and director nominations (via Schedule 14N) is April 28, 2025.
Microbot Medical Inc. presented clinical data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The data indicates successful robotic navigation and a significant reduction in radiation exposure.
📋 Key Facts
- Presented ACCESS-PVI pivotal trial data at the SIR annual meeting on April 9, 2025.
- Achieved a 100% success rate in robotic navigation across all cases (N=20).
- Reported zero Adverse Device Events (ADE=0%) during the follow-up period.
- Demonstrated a mean 92% relative reduction in radiation exposure compared to control.
- Median robotic navigation time to target was 3 minutes.
- Physicians reported a 100% satisfaction rate with the LIBERTY system.
Microbot Medical Inc. announced that clinical data from its ACCESS-PVI trial will be presented via a podium presentation at an upcoming medical conference. The company also reaffirmed its expectation for an FDA decision regarding 510(K) clearance of LIBERTY during Q2 2025.
📋 Key Facts
- ACCESS-PVI trial data to be presented by Dr. Francois Cornelis (Memorial Sloan Kettering Cancer Center).
- Presentation is a podium presentation scheduled for April 2, 2025, at 11:33am CT.
- Company reaffirms expectation of FDA decision on LIBERTY 510(K) clearance within the current second quarter (Q2 2025).
Microbot Medical Inc. announced the appointment of Paul Mullen as the newly created Vice President of Sales. The role is focused on building U.S. sales infrastructure ahead of an anticipated FDA decision in Q2 2025.
📋 Key Facts
- Appointment of Paul Mullen to the new position of Vice President of Sales.
- Mullen will lead commercial sales in the United States and report directly to CEO Harel Gadot.
- The company reaffirmed its expectation of an FDA decision during the second quarter of 2025.
Microbot Medical Inc. announced successful feasibility results from a research collaboration with Corewell Health regarding its LIBERTY Endovascular Robotic System. The study demonstrated remote telesurgery capabilities in a coronary simulation model across two facilities located 5 miles apart.
🚩 Red Flags
- The telesurgery feature is still under development and is not covered under the Company’s current pending 510(k) premarket submission with the FDA.
📋 Key Facts
- Research collaboration with Corewell Health demonstrated the feasibility of using the LIBERTY Endovascular Robotic System between separate and remote facilities.
- The project utilized a coronary simulation model to assess simulated cardiovascular interventional procedures.
- Results are scheduled for presentation at the Cardiovascular Research Technologies (CRT) annual meeting (March 8-11, 2025).
- Findings will be published in the Journal of the American College of Cardiology (JACC) Interventions online edition.
Microbot Medical Inc. closed a registered direct offering of 6,103,289 shares at $2.13 per share and a concurrent private placement of unregistered short-term series I preferred investment options.
🚩 Red Flags
- Significant potential dilution: The issuance of preferred options could result in up to 12,206,578 new shares being issued, effectively doubling the current offering's share count.
- Capital raising activity often indicates a need for immediate liquidity/cash runway extension.
📋 Key Facts
- Closed a registered direct offering of 6,103,289 common shares at $2.13 per share.
- Issued unregistered short-term series I preferred investment options in a concurrent private placement.
- Preferred options allow for the purchase of up to 12,206,578 shares of common stock.
- Exercise price for preferred options is set at $2.13 per share.
- Options are exercisable for two years following specific stockholder approval/authorization dates.
Microbot Medical Inc. announced a dual-track financing consisting of a $13.0 million registered direct offering and a concurrent private placement involving Series I Warrants. The deal includes significant warrant coverage for both investors and the placement agent, which will require stockholder approval and an increase in authorized shares.
🚩 Red Flags
- Significant Dilution: The issuance of Series I Warrants (12.2M shares) represents substantial potential dilution compared to the current share count.
- Warrant Overhang: Extensive warrants issued to investors and the placement agent create long-term selling pressure.
- Capital Raise Necessity: The scale of the offering suggests a need for immediate liquidity to fund operations.
📋 Key Facts
- Registered Direct Offering: 6,103,289 shares at $2.13 per share (approx. $13.0 million gross proceeds).
- Private Placement: Issuance of Series I Warrants to purchase up to 12,206,578 shares of Common Stock.
- Warrant Exercise Price: $2.13 per share for both Series I and Registered Offering shares.
- Placement Agent: H.C. Wainwright & Co., LLC; receiving 7% cash fee + 1% management fee, plus warrants for 305,164 shares at $2.6625/share.
- Warrant Coverage: Series I Warrants represent significant potential dilution (nearly double the number of shares in the direct offering).
- Required Actions: Company must hold a meeting within 90 days to approve an increase in authorized shares for warrant exercise.
Microbot Medical Inc. completed two significant registered direct offerings in January 2025, raising approximately $15.6 million in gross proceeds to fund ongoing R&D and anticipated commercialization. The company also announced the completion of its At-the-Market (ATM) offering program.
🚩 Red Flags
- Significant dilution: The company issued over 7.7 million new shares across two offerings, significantly increasing the share count (24,242,120 total outstanding as of Jan 7, 2025).
- Continuous cash burn: Company has incurred cumulative losses of ~$87.5M since inception and anticipates continued net losses for the foreseeable future.
- Geopolitical risk: Operations are primarily based in Israel; ongoing military activities pose risks to supply chains and clinical/regulatory milestones.
📋 Key Facts
- Closed a registered direct offering on Jan 7, 2025, raising ~$7.0M at $1.75/share via common stock and series G preferred investment options.
- Closed a second registered direct offering on Jan 10, 2025, raising ~$8.6M at $2.27/share via common stock and series H preferred investment options.
- Completed the use of an ATM offering program that raised a total of $4,819,278 in gross proceeds through Jan 7, 2025.
- Total cash raised in January 2025 across both offerings was approximately $15.6 million (gross).
- Anticipates FDA marketing clearance for the LIBERTY® Endovascular Robotic Surgical System in Q2 2025.
Microbot Medical Inc. announced salary and bonus increases for three key executives (CTO, CFO, and CMO) effective for the 2025 fiscal year.
🚩 Red Flags
- Compensation increases in a micro-cap environment can sometimes signal cash burn concerns or misalignment with shareholder interests, though these are standard administrative updates.
- The use of NIS (Israeli New Shekel) for compensation indicates significant operational exposure to Israel/foreign currency fluctuations.
📋 Key Facts
- Simon Sharon (CTO/GM Israel): Annual base salary increased to NIS 960,000 starting FY 2025.
- Rachel Vaknin (CFO): Annual base salary increased to NIS 720,000 and monthly travel benefits increased from NIS 1,000 to NIS 5,000.
- Juan Diaz-Cartelle (CMO): Maximum annual bonus increased from 30% to 35% of base salary for FY 2025.
Microbot Medical Inc. announced the acceptance of a late-breaking abstract for its ACCESS-PVI trial to be presented at the Society of Interventional Radiology (SIR) annual meeting in March 2025.
📋 Key Facts
- The company's ACCESS-PVI trial data will receive a podium presentation at the SIR annual meeting.
- The meeting is scheduled for March 29 - April 2, 2025, in Nashville, TN.
- The clinical trial evaluates the performance and safety of LIBERTY® in patients undergoing peripheral vascular interventions.
Microbot Medical Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock closed at or above $1.00 for 15 consecutive business days.
🚩 Red Flags
- Historical delisting risk (the company was previously in violation of minimum bid requirements).
📋 Key Facts
- The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
- Compliance was achieved by maintaining a minimum closing bid price of at least $1.00 per share for 15 consecutive business days.
- The compliance period spanned from December 26, 2024, to January 17, 2025.
- Nasdaq considers the prior bid price deficiency matter officially closed.
Microbot Medical Inc. announced a special bonus authorization for its CEO, President, and Chairman, Harel Gadot, in the amount of approximately $150,000.
🚩 Red Flags
- Related-party transaction involving the highest-ranking officer/insider.
- Timing of bonus authorization may warrant scrutiny depending on company cash position (not specified in filing).
📋 Key Facts
- Special bonus authorized on January 17, 2025.
- Recipient: Harel Gadot (CEO, President, and Chairman).
- Bonus Amount: Approximately $150,000.
Microbot Medical Inc. announced the appointment of Michal Ahuvia as the new Director of Operations. The role is focused on scaling production efficiencies ahead of the anticipated commercial launch of LIBERTY in Q2 2025.
📋 Key Facts
- Appointment of Michal Ahuvia to the newly created position of Director of Operations.
- Primary mandate: Ramp-up production and improve manufacturing efficiencies.
- Commercial launch of 'LIBERTY' product is anticipated in the second quarter (Q2) of 2025.
Microbot Medical Inc. announced a dual-track financing consisting of a $8.6 million registered direct offering and a concurrent private placement involving Series H preferred investment options (warrants). The deal includes significant warrants issued to the placement agent, H.C. Wainwright & Co., LLC.
🚩 Red Flags
- Significant dilution potential from both the direct offering shares and the large volume of Series H warrants (7.5M+ shares).
- Complex warrant structures including 'Wainwright Warrants' that trigger additional equity issuance upon exercise of investor warrants.
- High cost of capital: The placement agent receives significant cash fees plus multiple layers of warrants.
📋 Key Facts
- Registered Direct Offering: 3,788,550 shares at $2.27 per share for approximately $8.6 million gross proceeds.
- Private Placement: Issuance of Series H preferred investment options to purchase up to 7,577,100 shares of Common Stock at an exercise price of $2.10 per share.
- Wainwright Warrants: The placement agent received warrants for 189,428 shares with an exercise price of $2.8375 per share.
- Agent Compensation: H.C. Wainwright & Co., LLC to receive a 7.0% cash fee and a 1.0% management fee on gross proceeds, plus various expense reimbursements.
- Expected Closing Date: On or about January 10, 2025.
Microbot Medical Inc. announced a dual-track financing consisting of a $7.0 million registered direct offering and a concurrent private placement of Series G preferred investment options (warrants). The offering includes significant warrant coverage for both investors and the placement agent, H.C. Wainwright & Co.
🚩 Red Flags
- Significant Dilution: The issuance of up to 8 million warrants (Series G) plus the 4 million new shares represents massive potential dilution for existing shareholders.
- High Warrant Coverage: The private placement includes a 1:1 warrant ratio (8M warrants for 8M potential shares), which is highly dilutive.
- Complex Fee Structure: Extensive compensation for H.C. Wainwright, including cash fees and additional warrants triggered by the exercise of investor warrants.
📋 Key Facts
- Registered Direct Offering: 4,000,001 shares at $1.75 per share, totaling ~$7.0 million gross proceeds.
- Private Placement: Series G preferred investment options to purchase up to 8,000,002 shares of Common Stock at an exercise price of $1.75 per share.
- Warrant Coverage: Investors receive warrants for the full amount of the private placement; H.C. Wainwright receives 200,000 warrants with an exercise price of $2.1875.
- Placement Agent Fees: H.C. Wainwright to receive a 7% cash fee and a 1% management fee on gross proceeds, plus various expense reimbursements.
- Warrant Terms: Series G Warrants expire in two years; Wainwright Warrants also expire in two years.
- Expected Closing: On or about January 7, 2025.
Microbot Medical Inc. has fully utilized its $4.8 million At-the-Market (ATM) offering agreement with H.C. Wainwright & Co. LLC. As of January 3, 2025, the company has sold all available shares under this specific program.
🚩 Red Flags
- The company has exhausted its current ATM capacity, which may necessitate a new equity offering (dilution) to fund future operations.
- Heavy reliance on ATM offerings suggests continuous need for external capital to sustain operations.
📋 Key Facts
- The ATM Agreement was originally entered into on June 10, 2021, and amended on July 1, 2024.
- Aggregate offering price limit was $4,819,905.
- Total shares sold under the agreement through January 3, 2025: 4,276,486 shares.
- Gross proceeds generated from sales: $4,819,278.
- Aggregate placement fees and expenses deducted: $144,578.
- Total common stock issued and outstanding as of January 3, 2025: 20,242,119 shares.
Microbot Medical Inc. issued a press release summarizing its 2024 milestones and outlining its strategic shift toward the commercial launch of its LIBERTY Endovascular Robotic Surgical System in 2025.
📋 Key Facts
- Company achieved several key milestones throughout 2024.
- Strategic focus is shifting toward the commercial launch of the LIBERTY Endovascular Robotic Surgical System.
- The company is preparing for market entry in 2025.
Microbot Medical Inc. announced the results of its Annual Meeting held on December 17, 2024, which included the election of David J. Wilson to the Board of Directors and approval of an amendment to the Omnibus Performance Award Plan.
🚩 Red Flags
- The increase in authorized shares under the Omnibus Performance Award Plan (600k additional shares) represents potential future dilution for existing shareholders.
📋 Key Facts
- David J. Wilson was elected as a Class III director for a three-year term effective December 17, 2024.
- Mr. Wilson was appointed to the Audit Committee and Compensation Committee, filling vacancies left by Yoseph Bornstein.
- Stockholders approved an amendment to the 2020 Omnibus Performance Award Plan to increase reserved shares from 2,020,652 to 2,620,652 (an increase of 600,000 shares).
- Stockholders ratified Brightman Almagor Zohar & Co. (Deloitte affiliate) as the independent registered public accounting firm for the year ending December 31, 2024.
- David J. Wilson brings extensive medical device leadership experience from roles at InnovHeart Corporation, Haemonetics, and Johnson & Johnson.
Microbot Medical Inc. has submitted a 510(k) premarket notification to the FDA for its LIBERTY® Endovascular Robotic System following successful clinical trial completion. The company expects FDA marketing clearance in Q2 2025, which would trigger U.S. commercialization activities.
📋 Key Facts
- Submitted 510(k) premarket notification to the FDA for LIBERTY® Endovascular Robotic System on December 10, 2024.
- Submission follows a multi-center, single-arm trial evaluating performance and safety in human subjects for Peripheral Vascular Interventions.
- Anticipated FDA marketing clearance: Second Quarter of 2025.
- U.S. commercialization is expected to commence following regulatory clearance.
Microbot Medical Inc. has released updated investor presentation materials via its website and as an exhibit to this Form 8-K.
📋 Key Facts
- The company released updated presentation materials on October 31, 2024.
- Materials are available in the 'Investors' section of the company's website under 'IR Resources'.
- The information is furnished pursuant to Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Microbot Medical Inc. announced the successful completion of patient enrollment and follow-up for its ACCESS-PVI human clinical trial. The company is preparing for an FDA 510(k) submission by year-end 2024 and anticipates commercial infrastructure expansion following expected FDA clearance in Q2 2025.
📋 Key Facts
- Completed enrollment and follow-up for all patients in the ACCESS-PVI human clinical trial.
- On track to file a 510(k) submission with the FDA by the end of 2024.
- Anticipates FDA clearance during the second quarter of 2025.
- Plans to hire a seasoned healthcare executive to lead sales efforts upon FDA clearance.
Microbot Medical Inc. received a deficiency letter from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share. The company has until April 7, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice (non-compliance with minimum bid price).
- Potential for mandatory reverse stock split to maintain listing.
- Risk of delisting if compliance is not met by April 2025.
📋 Key Facts
- Received Nasdaq deficiency letter on October 9, 2024.
- Violation of Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Stock price was below $1.00 for 30 consecutive business days between August 26, 2024, and October 7, 2024.
- Compliance period expires on April 7, 2025.
- To regain compliance via a second compliance period, the company may need to effect a reverse stock split.
Microbot Medical Inc. announced an acceleration in patient enrollment for its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System. The company expects to complete the trial ahead of schedule and remains on track for a 510(k) FDA submission by year-end 2024.
📋 Key Facts
- 80% of patients in the ACCESS-PVI clinical trial have completed the follow-up period due to accelerated enrollment.
- The company anticipates completing the clinical trial ahead of its original timeline.
- FDA 510(k) submission is still on track for completion by the end of 2024.
- Successfully completed all biocompatibility tests required by the Investigational Device Exemption (IDE) application.
- Received full approval for the IDE study from the FDA.
Microbot Medical Inc. announced a significant clinical milestone regarding its LIBERTY Endovascular Robotic Surgical System. The company has reached the midpoint of its ACCESS-PVI pivotal human clinical trial, having enrolled and completed follow-up for 50% of participants.
📋 Key Facts
- Reached midpoint of ACCESS-PVI pivotal human clinical trial (50% enrollment/follow-up complete).
- Expects to complete full enrollment and follow-up in Q4 2024.
- Plans to file 510(k) submission with the FDA by the end of 2024.
- Biocompatibility results have been submitted to the FDA as part of the IDE application.
Microbot Medical Inc. filed an 8-K to furnish updated investor presentation materials via Item 7.01 (Regulation FD Disclosure). The filing does not contain new material non-public information but provides a mechanism for investors to access updated company resources.
📋 Key Facts
- The Company released updated presentation materials on September 11, 2024.
- Materials are intended to be available on the 'Investors' section of the company website by September 12, 2024.
- Information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Microbot Medical Inc. has entered into a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures. The partnership focuses on developing capabilities for simulated cardiovascular interventional procedures using the LIBERTY Endovascular Robotic System across two geographically separated sites.
📋 Key Facts
- Entered into a Phase 2 collaboration agreement with Corewell Health TM.
- Objective: Advance remote telesurgery for endovascular procedures.
- Phase 2 scope: Develop capabilities to perform simulated cardiovascular interventional procedures using the LIBERTY Endovascular Robotic System.
- Testing will occur across two sites within the Corewell Health system located five miles apart.
Microbot Medical Inc. announced it has achieved ISO 13485:2016 certification for its quality management system. This certification is a prerequisite for obtaining the CE mark required for sales in the European Union and aligns with upcoming FDA regulatory transitions.
📋 Key Facts
- Company received ISO 13485:2016 certification for its quality management system on August 13, 2024.
- Certification is a requirement for obtaining CE mark approval for sales in the European Union.
- The certification is expected to streamline the transition into the revised FDA Quality System Management Regulation (QMSR).
Microbot Medical Inc. has entered into an agreement with Emory University to explore a potential collaboration involving autonomous robotics in endovascular procedures. The partnership aims to evaluate the feasibility of integrating the company's LIBERTY® Endovascular Robotic Surgical System with imaging systems.
📋 Key Facts
- Agreement signed with Emory University on August 1, 2024.
- Purpose: Evaluate and explore potential future collaboration in autonomous robotics for endovascular procedures.
- Technical focus: Integrating the LIBERTY® Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system.
Microbot Medical Inc. announced the completion of clinical site enrollment for its pivotal human clinical trial following the addition of Memorial Sloan Kettering Cancer Center. The company intends to use these results to support future FDA marketing submissions and commercialization of its LIBERTY Endovascular Robotic Surgical System.
📋 Key Facts
- Completed enrollment of clinical sites for pivotal human clinical trial.
- Added Memorial Sloan Kettering Cancer Center as a clinical site in New York.
- The trial is being conducted under an Investigational Device Exemption (IDE).
- Trial results are intended to support future FDA marketing submission and commercialization.
Microbot Medical Inc. announced the successful completion of the first clinical procedure at Baptist Hospital of Miami using its LIBERTY® Endovascular Robotic Surgical System. This milestone is part of the company's pivotal human clinical trial under an Investigational Device Exemption (IDE).
📋 Key Facts
- Baptist Hospital of Miami is the second site to perform clinical procedures for the company's Pivotal Human Clinical Trial.
- The first procedure at this site was completed successfully using the LIBERTY® Endovascular Robotic Surgical System.
- The trial is being conducted under an Investigational Device Exemption (IDE).
- Clinical results are expected to support future FDA submission and commercialization.
Microbot Medical Inc. announced the successful completion of its first patient procedure using the LIBERTY Endovascular Robotic Surgical System at Brigham and Women’s Hospital. This procedure is part of a pivotal human clinical trial under an Investigational Device Exemption (IDE) aimed at supporting future FDA submission.
📋 Key Facts
- Completed first patient procedure utilizing the LIBERTY Endovascular Robotic Surgical System.
- Procedure performed at Brigham and Women’s Hospital.
- The procedure is part of a pivotal human clinical trial under an Investigational Device Exemption (IDE).
- Clinical results are intended to support future FDA submission and commercialization.
Microbot Medical Inc. announced it has secured Institutional Review Board (IRB) approval and signed a Clinical Trial Agreement with Baptist Hospital of Miami. This marks the second clinical trial site for the pivotal human clinical trial of its LIBERTY Endovascular Robotic Surgical System under an Investigational Device Exemption (IDE).
📋 Key Facts
- Signed a Clinical Trial Agreement with Baptist Hospital of Miami.
- Received Institutional Review Board (IRB) approval from Baptist Hospital of Miami.
- Baptist Hospital includes Miami Cardiac & Vascular Institute and Miami Cancer Institute.
- This is the second announced site for the pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System.
- The trial is being conducted as part of the Company's Investigational Device Exemption (IDE).
Microbot Medical Inc. has amended its At the Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to align with a new prospectus supplement under its 2023 Registration Statement. This allows for the potential sale of common stock up to an aggregate price of $4,819,905.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- The relatively small aggregate amount ($4.8M) suggests a need for continuous capital infusion typical of micro-cap biotech companies.
📋 Key Facts
- Amended Sales Agreement dated July 1, 2024, with H.C. Wainwright & Co., LLC.
- The offering is part of an 'at the market' (ATM) program under a previously declared effective 2023 Registration Statement.
- Aggregate offering price limit: $4,819,905.
- Shares will be sold via Nasdaq, market makers, or negotiated transactions at prevailing market prices.
Microbot Medical Inc. announced that Brigham and Women’s Hospital will serve as a clinical trial site for the pivotal human clinical trial of its LIBERTY Endovascular Robotic Surgical System. The hospital has completed the Site Initiation Visit and received investigational units.
📋 Key Facts
- Brigham and Women's Hospital (a leading academic medical center) is participating in the pivotal human clinical trial.
- The trial is part of the company's Investigational Device Exemption (IDE) application for the LIBERTY Endovascular Robotic Surgical System.
- Site Initiation Visit has been completed, including training on clinical study protocols.
- Investigational units have been shipped to and received by the hospital.
Microbot Medical Inc. announced a dual-track financing consisting of a $2.35 million registered direct offering and a concurrent private placement involving Series F warrants. The transaction includes significant warrant issuance to the placement agent and investors, which will likely result in substantial dilution.
🚩 Red Flags
- Significant Dilution Risk: The issuance of up to 3.1M warrants (Series F) plus the 1.56M shares in the direct offering represents a large increase in share count.
- Warrant Overhang: Extensive use of warrants for both investors and the placement agent can create downward pressure on the stock price upon exercise.
- High Cost of Capital: The combination of cash fees (8% total) and various warrant issuances to the agent is expensive for a micro-cap company.
📋 Key Facts
- Registered Direct Offering: 1,566,669 shares of common stock at $1.50 per share.
- Aggregate gross proceeds from the offering: approximately $2.35 million (before fees).
- Private Placement: Issuance of Series F preferred investment options to purchase up to 3,133,338 shares of Common Stock at an exercise price of $1.50 per share.
- Wainwright Warrants: The placement agent received warrants to purchase 78,333 shares at an exercise price of $1.875 per share.
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive a 7.0% cash fee and a 1.0% management fee on gross proceeds.
Microbot Medical Inc. announced that it has received FDA approval to proceed with its pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System under an Investigational Device Exemption (IDE). The company has already signed a service agreement with a leading academic medical center and is expanding its clinical sites.
📋 Key Facts
- FDA approved the pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System via IDE application.
- The study will be conducted in the United States.
- A clinical trial service agreement has been signed with a leading academic medical center.
- The company is currently completing required biocompatibility tests as part of the IDE process.
Microbot Medical Inc. announced the successful completion of the first phase of its collaboration with Corewell Health. The phase demonstrated the technical capabilities of the LIBERTY® System in a pre-clinical study, focusing on coronary guidewire and stent delivery.
📋 Key Facts
- Completed the first phase of a multi-phase collaboration with Corewell Health as of April 29, 2024.
- The collaboration aims to enable telerobotics between remote centers using the LIBERTY® System.
- Results were published in the Journal of the American College of Cardiology: Cardiovascular Interventions.
- The study highlighted technical success in coronary guidewire and stent delivery via a miniaturized robotic system.
Microbot Medical Inc. updated its investor presentation materials and provided guidance on expected regulatory milestones for its products.
📋 Key Facts
- Company anticipates receiving US FDA 510(k) clearance in the first half of 2025.
- Company anticipates receiving CE Mark approval in the second half of 2025.
- Updated presentation materials were posted to the company's website and furnished as Exhibit 99.1.
Microbot Medical Inc. issued a press release confirming that operations in Israel and the USA continue without interruption despite regional geopolitical tensions. The company reaffirmed its commitment to meeting regulatory milestones for its LIBERTY Endovascular Robotic Surgical System.
🚩 Red Flags
- Geopolitical risk implied by the need to clarify that operations in Israel are continuing without interruption.
📋 Key Facts
- Operations in Israel, USA, and globally are continuing without interruption as of April 15, 2024.
- The company expects to meet currently planned timelines and milestones.
- FDA IDE submission is ongoing with the goal of commencing pivotal human studies as planned.
- Internal audit for ISO 13485 certification was successfully completed; audits are expected in 2024 to support CE approval in Europe.
- Sufficient inventory of the LIBERTY Endovascular Robotic Surgical System has been established for upcoming pivotal studies.
- The company has executed an initial phase partnership with one clinical partner and is in advanced discussions with others regarding AI and remote operation capabilities.
Microbot Medical Inc. announced an increase in the maximum annual bonus for its Chief Financial Officer, Rachel Vaknin, effective for the 2024 fiscal year.
📋 Key Facts
- Effective date of compensation change: February 22, 2024.
- CFO Rachel Vaknin's maximum annual bonus increased from 25% to 35% of base salary.
- All other terms of the CFO's compensation arrangement remain unchanged.
Microbot Medical Inc. has entered into a settlement agreement to resolve litigation involving allegations of fraudulent inducement and breach of representations related to a 2017 equity financing. The settlement involves a total payment of $2,154,000, consisting of $1,100,000 in cash (covered by insurance) and 1,005,965 shares of restricted common stock.
🚩 Red Flags
- Significant dilution risk: The issuance of over 1 million restricted shares requires a registration statement, which may lead to immediate selling pressure once effective.
- Legal/Litigation history: Settlement involves allegations of 'fraudulently inducing' investors into a previous financing agreement.
- Potential for further cash outflows if the company fails to register or remove restrictions on the settlement shares.
📋 Key Facts
- Settlement amount: $2,154,000 total ($1.1M cash via insurance; $1,054,000 in equity).
- Equity component consists of 1,005,965 shares of restricted common stock.
- The company must file an S-1 or S-3 registration statement for the shares within 30 days (by late February 2024).
- Plaintiffs will discontinue the lawsuit with prejudice upon receipt of settlement terms.
- Company submitted an Investigational Device Exemption (IDE) application to the FDA on January 29, 2024.
Microbot Medical Inc. announced the hiring of a US-based Clinical Research Associate (CRA) to support its upcoming Investigational Device Exemption (IDE) submission and first-in-human clinical trials.
📋 Key Facts
- Company hired a new US-based Clinical Research Associate (CRA).
- The hire is intended to support the anticipated IDE submission for human clinical trials.
- The move follows positive results from the company's pivotal GLP Pre-Clinical Study.
- The clinical team is led by Chief Medical Officer Dr. Juan Diaz-Cartelle.
Microbot Medical Inc. announced the reinstatement of annual fees for independent Board members and the full reinstatement of compensation for CEO Harel Gadot, effective January 1, 2024.
🚩 Red Flags
- The reinstatement of executive and director compensation suggests the company may be moving away from its previous emergency 'cost reduction' phase, though it does not explicitly signal financial distress or recovery.
📋 Key Facts
- Board of Directors authorized reinstatement of annual fees for independent members as of Jan 1, 2024.
- CEO/President/Chairman Harel Gadot's compensation is being reinstated in full as of Jan 1, 2024.
- Previous fee suspensions and pay cuts were implemented in May 2023 as part of a cost reduction plan.
Microbot Medical Inc. entered into an inducement offer to allow existing option holders to exercise options at a significantly reduced price ($1.62 vs. original prices up to $3.19) in exchange for new investment options. The company expects to raise approximately $2.73 million in gross proceeds.
🚩 Red Flags
- Significant dilution: The issuance of over 1.6 million new inducement options at $1.50 represents substantial potential dilution for existing shareholders.
- Downround/Price reduction: Existing holders are being incentivized to exercise at a price ($1.62) significantly lower than previous strike prices (up to $3.19), signaling a need for immediate liquidity and potentially distressed valuation.
- Warrant-like features: The inducement options have long durations (5.5 years) and cashless exercise provisions, which can act as 'overhang' on the stock price.
📋 Key Facts
- The transaction involves 1,685,682 shares of common stock at a reduced exercise price of $1.62 per share.
- New 'Inducement Investment Options' will be issued with an exercise price of $1.50 per share and a duration of 5.5 years.
- Gross proceeds are estimated at approximately $2.73 million before fees.
- H.C. Wainwright & Co., LLC is acting as the exclusive placement agent, receiving a 7% cash fee and a 1% management fee on gross proceeds.
- The company will file a registration statement (Form S-3 or S-1) to cover the resale of these shares within 30 days.